MarketPeel
Insider Trading Intelligence
DS

Devin Whittemore Smith

IOBT
GENERAL COUNSEL · IO BIOTECH, INC. · CIK 0001747818
FILING MIX · LIFETIME100%/0%
BUYS
9
SELLS
0
TOTAL VALUE
$19.7K
COMPANIES
2
ACTIVE SINCE
Dec 2019
HOLDINGS NOW
225,000
AVG SELL PX
TRADE KIND
SHOWING 9 / 9
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 1 pending
Forward-return performance of every backtestable P/S trade by Devin Whittemore Smith, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%+5.90%-1.09%+6.99%+6.99%
14d1+100.00%+0.97%+0.11%+0.85%+0.85%
30d1+100.00%+1.18%+1.98%-0.80%-0.80%
60d1+100.00%+23.65%+0.88%+22.77%+22.77%
90d1+100.00%+12.41%-3.17%+15.59%+15.59%
180d1+100.00%+46.13%+0.23%+45.90%+45.90%
1y1+0.00%-21.31%+16.03%-37.34%-37.34%
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
IOBT · 140,000 shares · as of Apr 2, 2025
046,25092,500138,750185,00020242025SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2019
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
FLOW · 9 buys / 0 sellsCOVERAGE · 23 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
IOBT
IO BIOTECH, INC.
PURCHASEGRANT
Stock grant
140,000140,000Apr 2, 2025Apr 4, 2025View →
IOBT
IO BIOTECH, INC.
PURCHASE
General Counsel
12,000$0.81$9.7K16,938Dec 23, 2024Dec 23, 2024View →
IOBT
IO BIOTECH, INC.
PURCHASEGRANT
Stock grant
185,000185,000Mar 15, 2024Mar 18, 2024View →
IOBT
IO BIOTECH, INC.
PURCHASEGRANT
Stock grant
4,938$1.90$9.4K4,938Aug 9, 2023Aug 9, 2023View →
IOBT
IO BIOTECH, INC.
PURCHASEGRANT
Stock grant
4,938$0.13$6174,938Aug 9, 2023Aug 9, 2023View →
IOBT
IO BIOTECH, INC.
PURCHASEGRANT
Stock grant
150,000150,000Jan 12, 2023Jan 13, 2023View →
NERV
MINERVA NEUROSCIENCES, INC.
PURCHASEGRANT
Stock grant
85,00085,000Oct 13, 2020Oct 14, 2020View →
NERV
MINERVA NEUROSCIENCES, INC.
PURCHASEGRANT
Stock grant
153,531153,531Jun 19, 2020Aug 17, 2020View →
NERV
MINERVA NEUROSCIENCES, INC.
PURCHASEGRANT
Stock grant
41,46941,469Dec 31, 2019Jan 3, 2020View →
Other insiders · IOBT
Loading peer insiders…
About this filer
CIK 0001747818
ROLE
General Counsel
PRIMARY
IOBT
COMPANIES
2
ACTIVE SINCE
Dec 2019
MARKETPEEL · /INSIDER/0001747818DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback